• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

CORD files for premarket approval with FDA for the SC9 IOL for cataract surgery


CORD, LLC, announced it has submitted a Premarket Approval (PMA) application to the FDA for the Model SC9 IOL for the treatment of cataracts.

The SC9 was developed by Stuart Cumming, MD, FACS, FRCOphth, who has been involved in the development of technology to improve and enhance vision for more than four decades. He holds more than 100 patents related to intraocular lenses.

Cumming designed the Crystalens, approved by the FDA in 2003.

The SC9 lens was designed to treat cataract patients with a single focus spherical optic and a rigid structure to consistently locate the optic in a position intended to provide intermediate vision that is superior to that of a standard monofocal IOL.

CORD is seeking market approval of the SC9 intraocular lens based on the results of more than 300 patients who were followed for a minimum of one year under an approved Investigational Device Exemption (IDE).

Related Videos
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
Elizabeth Yeu, MD, highlights from a corneal case report for a patient undergoing the triple procedure
William F. Wiley, MD, shares some key takeaways from his ASCRS presentation on binocularity and aperture optics.
© 2024 MJH Life Sciences

All rights reserved.